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Somatostatin analogs (SSA) are well-established antisecretory drugs in functionally active 
neuroendocrine tumors (NET). Two placebo-controlled trials have recently demonstrated 
significant improvement of progression-free survival under SSA treatment. Furthermore, 
somatostatin receptor (SSTR) overexpression in NET has also been utilized for diagnostic 
imaging and peptide receptor radionuclide therapy (PRRT). However, PRRT in NET is 
associated mostly with partial and minor remission, while other radionuclide therapies 
reach complete remissions in up to 75% of cases. This study assessed a potential radio-
sensitizing effect of SSA treatment in five established NET cell line models: BON, QGP-1, 
LCC-18, H727, and UMC-11. Irradiation was found to significantly inhibit proliferation, 
while no additional effect by octreotide treatment was observed. Intriguingly, no impact 
of SSA treatment alone was found in any of these NET cell lines when systematically 
analyzing cell viability, proliferation, and cell cycle distribution. Investigation of the causes 
for this octreotide resistance led to demonstration of low octreotide binding and scarce 
SSTR, specifically SSTR2 expression as compared to levels found in human NETs. 
The resistance toward SSA treatment in viability and proliferation assays could not be 
overcome by re-expression of SSTR2 in two of the cell lines. These results provide sys-
tematic evidence for a lack of authentic, tumor-like SSTR expression, and function in five 
frequently used NET cell line models and point to the need for more physiologic tumor 
model systems.
Keywords: neuroendocrine tumor, somatostatin receptor, somatostatin analog, cell line, octreotide, radiation 
sensitivity, peptide receptor radionuclide therapy,  expression
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inTrODUcTiOn
Somatostatin analogs (SSAs) are well-established antisecre-
tory drugs with a favorable safety profile that have been used 
as first-line treatment to control hormone hypersecretion in 
functionally active neuroendocrine tumors (NET) for more 
than 30  years (1, 2). Depot formulations of SSAs, lanreotide 
autogel, and long-acting repeatable (LAR) octreotide appear to 
be equally effective and well tolerated (3). The relevance of SSAs 
in antiproliferative treatment has been a matter of debate for the 
past two decades. However, two placebo-controlled trials have 
recently demonstrated significant improvement of progression-
free survival under SSA treatment (4, 5). The PROMID trial was 
a placebo-controlled, double-blind, randomized study evaluating 
the effect of octreotide LAR on tumor growth in patients with 
metastatic, well-differentiated midgut NET. The study showed 
that octreotide LAR significantly prolonged time to progression 
as compared with placebo (median time to tumor progression 
14.3 and 6  months, respectively) (4). More recently, another 
randomized, double-blind, placebo-controlled trial evaluated 
the effect of lanreotide in patients with metastatic, well- or mod-
erately differentiated, non-functional enteropancreatic NET (the 
CLARINET trial). It showed that lanreotide treatment resulted 
in a significantly extended progression-free survival as compared 
to placebo (median progression-free survival not reached vs. 
18 months) (5). As in the PROMID trial, this did not translate to 
increases in overall survival.
Somatostatin receptors (SSTR) comprise five closely 
related G protein-coupled receptors with high affinity to 
their cognate peptides, somatostatin-14 and somatostatin-28 
(6). SSTRs were cloned during the late 1990s from various 
species such as rat, mouse, and human. The five SSTR sub-
types showed a high degree of evolutionary conservation (7). 
In overexpression systems employing cell lines such as CHO, 
COS, and HEK293, SSTRs have shown to signal via the Gi 
pathway, thus lowering intracellular cAMP levels. In addi-
tion, various other signaling pathways and antiproliferative 
mechanisms for SSTRs have been described in these cellular 
models (8).
The overexpression of SSTRs in NETs as the basis for 
therapeutic approaches with SSAs had first been described 
during the 1980s. Autoradiographic detection of SSTRs using 
radioiodinated SSAs and in  situ hybridization were used at 
that time to demonstrate high overexpression in tumors with 
little background in other organs (9). With the availability of 
specific antibodies for SSTRs, these results could be confirmed 
using immunohistochemistry (10–12). Apart from direct 
pharmacological intervention for symptom control and anti-
proliferative action, SSTR overexpression in NET has also been 
utilized for targeted imaging and peptide receptor radionuclide 
therapy (PRRT) (13–16). PRRT using peptide conjugates such 
as DOTATOC and DOTATATE has evolved to be a major 
treatment option in the management of NETs and is associated 
mostly with partial and minor remission with objective response 
rates ranging from 4 to 30% (17). While other radionuclide 
treatments (radioiodine therapy for medullary thyroid cancer, 
radioimmunotherapy in B-cell non-Hodgkin’s lymphoma) 
reach high complete remission rates, drugs that act as radio-
sensitizers may improve PRRT success rates. Whether SSAs 
could sensitize tumors to radionuclide therapy is also of current 
clinical interest, as the first randomized multicenter PRRT trial 
in NET (NETTER-1) recently evaluated SSA treatment alone vs. 
a combination of PRRT plus SSA (18, 19).
This study was conceived to assess a potential radiosensitiz-
ing effect of SSA treatment in five established NET cell lines. 
The consequence of octreotide treatment before irradiation vs. 
irradiation only was to be determined. Further on, the impact 
of SSA treatment alone on these NET  cell lines was to be 
examined systematically by analyzing cell viability (metabolic 
activity), proliferation (cell number), and cell cycle distribu-
tion. Additional aims were to evaluate somatostatin binding 
and expression levels of all five SSTR subtypes in these cell 
lines. Finally, the impact of SSTR2 overexpression in two of 
the cell lines on viability under octreotide treatment was to be 
analyzed.
MaTerials anD MeThODs
If not indicated otherwise, cell culture reagents were obtained 
from Biochrom AG (Berlin, Germany) and chemicals, enzymes 
or dyes from Sigma Aldrich (Deisenhofen, Germany).
cell culture
The human neuroendocrine cell lines BON and QGP-1 
(pancreatic), LCC-18 (colonic), and H727 and UMC-11 
(pulmonary) were cultured in RPMI 1640 containing 10% 
fetal calf serum in a humidified atmosphere at 37°C with 
5% CO2. BON cells were a kind gift of Courtney Townsend 
(University of Texas, Galveston, TX, USA). LCC-18 cells 
were kindly donated by Kjell Öberg (University of Uppsala, 
Sweden). QGP-1 were obtained from the Japanese Collection 
of Research Bioresources, and H727 and UMC-11 from ATCC 
(Manassas, VA, USA). Cells were cultured for no longer than 
15 passages. All human cell lines have been authenticated by 
DSMZ (Braunschweig, Germany) using STR profiling. For 
QGP-1, UMC-11, and H727, DSMZ confirmed their identity 
as authentic. Due to the lack of reference profiles for BON 
and LCC-18, their respective STR profile was characterized as 
unique and not contaminated with any known cell line. The 
results of the STR profiling for BON and LCC-18 are provided 
in the table below.
D5 D5’ D13 D13’ D7 D7’ D16 D16’ vWa vWa’ Th01 Th01’ TPOX TPOX’ csF1 csF1’ amel amel’
BON 9 12 11 12 9 9 10 11 18 19 8.0 8.0 9.0 9.0 10 11 X Y
LCC-18 14 14 8 11 11 12 10 13 16 19 9.0 9.3 8.0 10.0 11 11 X X
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The recombinant cell lines BON-SSTR2 and QGP-1-SSTR2 
were generated by transfecting wild-type BON and QGP-1 
cells with pcDNA3.1-huSSTR2 (#SSTR200000, cDNA Resource 
Center, Bloomsberg, PA, USA; www.cdna.org) and jetPEI trans-
fection reagent (Polyplus-transfection, Illkirch, France). Positive 
clones were selected by addition of 600 μg/ml G-418 and tested for 
their SSTR2 expression by radioligand binding assay. RIN-1038 
were a kind gift from Jacques Philippe (University of Geneva, 
Switzerland) and were cultured in RPMI 1640 supplemented with 
10% fetal calf serum. RIN-1038-SSTR2-GFP cells were generated 
by stable transfection (see above) with a corresponding plasmid 
containing ratSSTR2-GFP. The transfected cell lines were con-
stantly maintained in RPMI 1640 supplemented with 10% fetal 
calf serum and 400 μg/ml G-418.
human Tissues
This study was carried out in accordance with the recommen-
dations and protocol approval by the local ethics committee at 
Charité—Universitätsmedizin Berlin with written informed 
consent from all subjects, in accordance with the Declaration of 
Helsinki. Sample characteristics are summarized in Table S2 in 
Supplementary Material.
reverse Transcription Quantitative real-
Time Pcr (rT-qPcr)
Total RNA was isolated from NET  cell lines or patient tissues 
using the RNeasy Mini Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s protocol. RNA was treated with DNase 
I (1  U/μg RNA) prior to reverse transcription with the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Waltham, MA, USA) according to the protocol supplied by the 
manufacturer. Quantitative real-time PCR was performed with 
SsoFast EvaGreen Supermix (Bio-Rad Laboratories, Hercules, 
CA, USA), 0.5 µM primer, and 30 ng cDNA in 10 µl total reaction 
volume on a Bio-Rad CFX96 Real-Time-System. PCR conditions 
were as follows: 98°C for 30  s, followed by 45 cycles of 98°C 
for 3  s and 60°C for 30  s. All primers were designed by using 
Primer3Plus, NCBI Primer-BLAST, and UCSC BLAT software. 
Primers were manufactured by Tib MolBiol (Berlin, Germany); 
their sequences are indicated in Table S1 in Supplementary 
Material. Plotted values were normalized to ALG9 and HPRT1 
using the ΔΔCt method (20). Reference genes were validated and 
chosen using geNorm algorithm by qbase+ software (Biogazelle, 
Ghent, Belgium).
Drug and radiation Treatment
Octreotide was synthesized by peptides & elephants (Hennigsdorf, 
Germany). For treatment, cells were seeded as desired and 
incubated overnight. The drug was always applied in medium 
on top of the wells at twofold concentration for final concentra-
tions between 0.001 nM and 10 µM. For experiments involving 
radiation, cells were irradiated 24 h after pretreatment using an 
external 137Cs source (GSR D1, Gamma-Service Medical, Leipzig, 
Germany) at a dose rate of 1 Gy/min and further incubated at 
37°C without medium change for the indicated time.
cell Viability and Proliferation assays
Cell lines were seeded in quadruplicates in 96-well plates at 
a density of 5,000 cells per well and grown overnight. Cells 
were treated with the indicated concentrations of octreotide 
in 100 µl medium per well. Metabolic activity and cell number 
were determined after another 96 h. For this, 100 µl medium 
containing AlamarBlue™ redox indicator (Thermo Fisher, 
Waltham, MA, USA) were added on top of each well, incubated 
for 3–4  h and the resulting fluorescence was measured using 
an EnVision Multilabel Plate Reader (Perkin Elmer, Waltham, 
MA, USA). Afterward, the supernatant was removed; cells were 
fixated with 4% v/v formaldehyde for 10 min and stained with 
1 µg/ml DAPI in PBS/0.1% v/v Triton for another 10 min. Four 
fields per well were imaged using an IN Cell Analyzer 1000 (GE 
Healthcare, Buckinghamshire, UK) with a 4× objective and 
nuclei were counted by Investigator software (GE Healthcare, 
Buckinghamshire, UK). All values were normalized to the 
control treated with vehicle, analyzed using GraphPad Prism 
5.04, and IC50 values were calculated by non-linear regression 
(variable slope, four parameter, least squares fit).
cell cycle analysis
Neuroendocrine tumor cell lines were seeded in 12-well plates 
in growth medium, cultured overnight, and treated as indicated. 
At distinct time points, cells including their supernatant were 
harvested and fixated in 70% ethanol for at least 24 h at −20°C. 
For cell cycle analysis, samples were washed with PBS, stained 
with propidium iodide solution (20  µg/ml propidium iodide, 
20 µg/ml RNaseA in PBS), and 10,000 events per sample were 
counted and analyzed using a FACSCalibur flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA).
internalization assay and 
immunofluorescence
Cells were grown on coverslips for at least 24 h. For internalization 
studies, they were incubated with or without 1 µM somatostatin-14 
(Bachem, Bubendorf, Switzerland) or octreotide (peptides 
& elephants, Hennigsdorf, Germany) in serum-free medium 
for 30 min at 37°C. Cells were washed with PBS, fixated in 1:1 
acetone/methanol for 2 min, and incubated with anti-SSTR2 pri-
mary antibody (sc365502, Santa Cruz Biotechnology, Dallas, TX, 
USA) diluted 1:50 in PBS overnight at 4°C. After washing with 
PBS, cells were incubated with a Cy3-conjugated goat anti-mouse 
secondary antibody (#115-165-146, Jackson ImmunoResearch, 
West Grove, PA, USA) diluted 1:1,000 in PBS for 1  h at room 
temperature. After washing with PBS, coverslips were briefly 
dipped into 96% ethanol, air-dried, and mounted on glass slides 
with Immu-Mount (Thermo Fisher Scientific, Waltham, MA, 
USA). Mounted cells were imaged using a confocal laser scan-
ning microscope (LSM510, Carl Zeiss, Jena, Germany) using a 
helium–neon laser at 543 nm, LP560 emission filter, and 40× or 
63× NeoFluar oil immersion objectives. RIN-1038-SSTR2-GFP 
cells were not immunostained after fixation, but otherwise treated 
the same. To visualize GFP fluorescence, an argon laser at 488 nm, 
LP505 emission filter was utilized on the same microscope.
FigUre 1 | Pretreatment with octreotide does not modulate the impact of irradiation on neuroendocrine tumor (NET) cell lines. NET cell lines were incubated with 
100 nM, 1 µM, or 10 µM octreotide or vehicle (control) for 24 h before irradiation. (a) Cell number was determined 96 h after irradiation with doses from 0 to 10 Gy. 
Graphs show mean ± SD of four replicates. (B,c) For assessment of cell cycle distribution, NET cells pretreated with vehicle (control) or 1 µM octreotide (oct) were 
collected 24 h after irradiation with 10 Gy (IR, oct + IR), stained with propidium iodide, and analyzed by flow cytometry. Data are shown as DNA histograms of one 
representative experiment (B) or as bar diagrams with mean ± SEM (n = 2–3) (c).
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radioligand Binding assay
Peptide iodination and radioligand-binding assays were 
performed as previously described (21). Briefly, 10 nmol Tyr11-
somatostatin-14 (Tyr11–SST14, Bachem, Bubendorf, Switzerland) 
were iodinated by the chloramin T method (22) with 1  mCi 
carrier-free Na125I (NEZ033L010MC, Perkin Elmer, Waltham, 
MA, USA) and purified by HPLC (Analytic HPLC 1200 Series, 
Agilent, Santa Clara, CA, USA) (see Figure S1 in Supplementary 
Material). For competitive radioligand binding assays, 40,000 
cells were seeded in 96-well plates and grown overnight. The 
next day, cells were incubated in binding buffer (50 mM Hepes, 
pH 7.4, 5  mM MgCl2, 1  mM CaCl2, 0.5% w/v BSA, cOmplete 
protease inhibitors) containing 100,000 counts per minute (cpm) 
[125I]-Tyr11-SST14 and increasing concentrations of unlabeled 
peptide. After 30 min at 37°C, cells were washed with ice-cold 
washing buffer (50 mM Tris–HCl, pH 7.4, 125 mM NaCl, 0.05% 
w/v BSA), lysed with 1 N NaOH, transferred to vials, and meas-
ured in a gamma counter (Wallac 1470 Wizard, Perkin Elmer, 
Waltham, MA, USA). The obtained cpm values were analyzed 
with GraphPad Prism 5.04, and IC50 values were calculated by 
non-linear regression (one site—fit logIC50, least squares fit).
resUlTs
In order to evaluate the influence of the SSA octreotide on the 
antiproliferative effect of radiation, five established NET  cell 
lines from different organs of origin were studied: BON and 
QGP-1 cells from pancreatic NET, LCC-18 from a colon NET, 
as well as H727 and UMC-11 cells originating from pulmonary 
NETs. To ensure generating the maximum possible effect, all 
these cells were incubated with or without 100  nM, 1  µM, or 
10 µM octreotide for 24 h before irradiating them with a single 
dose of 0–10 Gy using a 137Cs source. 96 h after irradiation, cells 
were stained using DAPI and nuclei were counted using a high-
content analysis system. Results show a clear dose-dependent 
antiproliferative effect of radiation in all cell lines investigated, 
as cell numbers are increasingly reduced by increasing radiation 
doses (Figure 1A). The dose required to lower cell numbers in 
this assay by 50% was about 4 to 6 Gy for all cell lines. However, 
pretreatment with octreotide did not result in a measurable effect 
on cell number in any of these cell lines, at any concentration, 
as dose-response curves look nearly identical for all treatment 
protocols (Figure  1A). Likewise, when cell cycle distribution 
FigUre 3 | Radioligand binding assay and gene expression analysis reveal lack of SSTR2 expression in neuroendocrine tumor (NET) cell lines. (a) For competitive 
radioligand binding, NET cell lines were incubated with 125Iodine-labeled Tyr11–somatostatin-14 and increasing concentrations of unlabeled somatostatin-14 or 
octreotide (0.01 nM–10 µM). Data represent mean ± SD from duplicate measurements. (B) Scatter plots showing relative gene expression levels from reverse 
transcription quantitative real-time PCR of SSTR1-5 in NET cell lines (n = 3, different passages) in comparison to control tissues (n = 10) and NET tissues (n = 20). 
Values were normalized to ALG9 and HPRT1. Bars represent the median value.
FigUre 2 | Octreotide treatment does not influence viability (metabolic activity) or proliferation (cell number) of neuroendocrine tumor (NET) cell lines. NET cell lines 
were treated with increasing concentrations of octreotide (0.001 nM–20 µM), incubated for 96 h and analyzed for metabolic activity (a) and cell number (B). Data 
represent mean ± SEM (n = 2) as percent of control treated with vehicle.
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after treatment was investigated, all cell lines demonstrated a 
strong G2/M arrest 24 h after irradiation. While under control 
conditions the G2/M fraction was about 20% for all cell lines, 
after irradiation it was highest in QGP-1 (73.9 ± 2.1%) and BON 
(63.3 ± 1.6%) and strongly increased in LCC-18 (55.0 ± 3.8%), 
H727 (50.9 ± 2.8%), and UMC-11 (48.5 ± 2.0%) (Figures 1B,C). 
Pretreatment with 1 µM octreotide did not modulate these effects. 
Intriguingly, 1 µM octreotide alone also did not change cell cycle 
distribution as compared to control, raising the question whether 
these NET cell lines were responsive to treatment with SSAs.
Two assays were utilized to address this question: a viability 
assay measuring the metabolic activity, and a cell counting 
assay to describe proliferation or cell death by determining the 
number of nuclei. In both assays, increasing concentrations of 
octreotide did not lead to any change. Metabolic activity as well 
as cell number, given as percent of control, remained unaffected 
across the whole concentration range for all five NET cell lines, 
thereby confirming their lack of responsiveness to SSA treatment 
(Figure 2).
As presentation of SSTR-binding sites at the cell surface is a 
prerequisite for functional response of NET cells to SSA treatment, 
a competitive radioligand binding assay was utilized to determine 
their binding capacity. While QGP-1, LCC-18, and H727 showed 
only background levels of [125I]-Tyr11-SST14 binding with no 
FigUre 4 | Validation of SSTR2 reintroduction into two neuroendocrine tumor (NET) cell lines. SSTR2 expression was confirmed by reverse transcription 
quantitative real-time PCR (a), competitive radioligand binding assay (B) and immunofluorescence staining (c,D) in BON-SSTR2 and QGP-1-SSTR2 in comparison 
to wild-type BON and QGP-1 cells. (a) SSTR2 gene expression level in NET cell lines (n = 3, different passages) in comparison to control tissues (n = 10) and NET 
tissues (n = 20). Values were normalized to ALG9 and HPRT1. Bars represent median. (B) Cells were incubated with 125Iodine-labeled Tyr11-somatostatin-14 and 
increasing concentrations of octreotide (0.01 nM–10 µM). Data represent mean ± SEM (n = 2). (c,D) SSTR2–staining of BON-SSTR2 and QGP-1-SSTR2 in 
comparison to wild-type cells (c) or after incubation with or without 1 µM somatostatin-14 (D). Scale bars represent 50 µm (c) or 10 µm (D).
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displacement by increasing amounts of either somatostatin-14 or 
octreotide, both BON and UMC-11 demonstrated binding above 
background that could be displaced by unlabeled somatostatin-14 
(IC50 values: 0.50 ±  0.16  nM in BON and 0.70 ±  0.29  nM in 
UMC-11), but not by octreotide, indicating a lack of binding sites 
for octreotide in all five NET cell lines (Figure 3A). In order to 
examine whether this absence of binding was due to insufficient 
expression, all five SSTR subtypes were analyzed by RT–qPCR 
for their mRNA expression in the five NET cell lines under investiga-
tion and, for comparison, in 10 human normal tissues (5 from 
pancreas, 5 from small intestine) as well as 20 human NET tissues 
(10 from pancreatic NET, 10 from small intestinal NET). In all five 
cell lines, the expression of the receptor subtype with the highest 
affinity for SSAs used in the clinic, SSTR2, was at or below the level 
of expression in normal tissues and more than one order of mag-
nitude lower than the median value of expression in NET tissues 
(Figure  3B). For BON, QGP-1, LCC-18, and UMC-11, SSTR2 
expression was at least two orders of magnitude lower than in NET 
tissues. The receptor with the second highest affinity for clinically 
used SSAs, SSTR5, is also expressed at or below the median of 
normal tissues in QGP-1, LCC-18, and UMC-11, while in BON 
and H727, it is expressed at levels close to NET tissues. SSTR3 has 
moderate affinity for octreotide and other SSAs. It shows mRNA 
levels close to those of NET tissues in BON and H727, whereas the 
levels in the other cell lines were below the expression in normal 
tissues. SSTR1 was found to be highly expressed in UMC-11 
(at the same level as in NET tissues), levels at or below normal tis-
sues were detected in BON, LCC-18, and QGP-1. SSTR1 expres-
sion was lowest in H727. SSTR4 mRNA levels were similarly low 
in normal and NET tissues, and they could not be detected in any 
of the cell lines (Figure 3B).
In summary, no octreotide binding was detected (Figure 3A) 
in any of the cell lines and mRNA levels for the preferred target 
of octreotide, SSTR2, were found to be at least 10-fold and up 
to 1,000-fold lower in NET  cell lines than in human NET tis-
sues (Figure  3B). Therefore, the lack of functional responses 
seen in viability, proliferation, and cell cycle analysis assays 
(Figures 1A–C and 2A,B) seemed likely to have its cause in low 
levels of SSTR2 expression in these cell lines. In order to rescue 
octreotide sensitivity, in two of the cell lines (BON, QGP-1) SSTR2 
was reintroduced by stable transfection with a plasmid encoding 
human SSTR2. The success of SSTR2 re-expression was tested by 
RT-qPCR, radioligand binding assay, immunofluorescence, and 
internalization assay (Figures 4A–D). Quantification of human 
SSTR2 mRNA by RT-qPCR demonstrated successful expression 
of the target in both BON-SSTR2 and QGP-1-SSTR2 cells, with 
mRNA levels about 1,000-fold higher than in wild-type BON 
and QGP-1 and similar to mRNA levels found in human NET 
tissues (Figure 4A). Consequently, considerably higher binding 
levels were detected in the [125I]-Tyr11-SST14 radioligand binding 
assay in transfected cells as compared to wild-type cells: 2.5-fold 
higher in BON-SSTR2 and 9-fold higher in QGP-1-SSTR2 
(Figure  4B). Importantly, this binding could be completely 
displaced by increasing concentrations of unlabeled octreotide 
at IC50 values in the expected subnanomolar to low nanomolar 
range (0.67 ±  0.32  nM for BON-SSTR2, 3.62 ±  0.23  nM for 
QGP-1-SSTR2). Similarly, immunofluorescence staining using 
a monoclonal antibody specific for human SSTR2 in wild-type 
BON and QGP-1 cells yielded only faint signals, whereas after 
reintroduction of SSTR2 into these cell lines, a clear staining 
signal was observed (Figure  4C). The distribution of SSTR2 
staining suggested a predominant localization of the receptor 
at the plasma membrane. Taken together, SSTR2 detection 
in transfected cells using RT-qPCR, radioligand binding, and 
immunofluorescence staining strongly suggested successful 
SSTR2 reintroduction into BON and QGP-1 cells, thereby lead-
ing to sufficient levels of plasma membrane receptors. To verify 
whether these receptors would also show functional activity, a 
microscopic internalization assay was performed. BON-SSTR2 
and QGP-1-SSTR2 were incubated for 30  min at 37°C under 
control conditions (medium only) or with 1 µM somatostatin-14 
in medium. Controls showed predominantly plasma membrane 
FigUre 5 | SSTR2 reintroduction does not sensitize human neuroendocrine 
tumor (NET) cells to octreotide treatment. (a) Human SSTR2-transfected 
NET cell lines BON and QGP-1 were treated with increasing concentrations 
of octreotide (0.1 pM–10 µM), incubated for 96 h and analyzed for viability 
(metabolic activity). (B) For comparison, wild-type and ratSSTR2-GFP-
transfected RIN-1038 cells were analyzed in the same way. Data represent 
mean ± SEM (n = 2–4).
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localization as seen before, whereas after incubation with the 
agonist, a more diffuse, punctate pattern was observed, indicat-
ing a functional, ligand-dependent SSTR2 internalization into 
an intracellular vesicle compartment (Figure  4D). Similarly, 
cells were incubated with or without octreotide to principally 
demonstrate that there is downstream activity of octreotide in 
SSTR2-transfected BON and QGP-1 cells. As data in Figure S2 in 
Supplementary Material shows, octreotide has a profound effect 
on SSTR2 distribution in these cells (as well as in rat RIN-1038 
cells transfected with a ratSSTR2-GFP plasmid). In the absence 
of ligand, the receptor localizes at the plasma membrane. Upon 
ligand addition, a translocation to an intracellular compartment 
becomes clearly visible (Figure S2 in Supplementary Material).
After demonstrating expression at NET-like levels and 
functional activation of the transfected SSTR2 in both cell lines, 
the functional consequences for viability of BON-SSTR2 and 
QGP-1-SSTR2 under SSA treatment were investigated. Both 
transfected cell lines were incubated with increasing concentra-
tions of octreotide (0.1 pM–10 µM). However, no activity of the 
SSTR2 agonist was detected in the viability assay (Figure  5A). 
To evaluate whether re-expression of SSTR2 in another cell line 
would be able to sensitize cells to octreotide, we overexpressed the 
GFP-tagged rat SSTR2 in the rat insulinoma cell line RIN-1038. 
When both wild-type RIN-1038 and RIN-1038-SSTR2-GFP were 
subjected to treatment with increasing concentrations of octreo-
tide, a difference was observed: while wild-type cells showed no 
octreotide response in viability, RIN-1038-SSTR2-GFP showed 
sensitivity toward octreotide with an IC50 of 2.29 ± 2.23 nM and 
an intrinsic activity of 31% (Figure 5B).
DiscUssiOn
Peptide receptor radionuclide therapy using peptides such as 
DOTATOC and DOTATATE has evolved to be a major treatment 
option in the management of NETs and is associated mostly with 
partial and minor remission with objective response rates ranging 
from 4 to 30% (17). While previous PRRT studies were typically 
performed as monocentric retrospective studies, the prospective 
multicenter NETTER-1 trial (PRRT plus SSA vs. SSA alone) has 
recently demonstrated similar results with regard to response rate 
and progression-free survival, with overall survival at interim 
analysis appearing very encouraging (18). However, in other 
therapeutic settings, nuclear therapies perform even better: in 
metastasized differentiated thyroid cancers, radioiodine therapy 
can achieve a complete remission in at least a third of patients 
(23). Radioimmunotherapy with anti-CD20 antibodies in B-cell 
non-Hodgkin’s lymphoma achieves complete responses in 75% 
of patients (24). In stark contrast, in PRRT using SSAs, complete 
remission is extremely rare despite the fact that a radiation dose 
of as high as 250 Gy can be delivered to the tumors (25). Other 
established NET therapies such as SSA treatment may have a 
positive or negative impact on response rates by either radio-
sensitizing or radioprotecting tumors before PRRT. Therefore, 
the initial experiments in this study were designed to evaluate a 
potential synergistic or antagonistic effect of combined radiation 
and octreotide treatment in five established NET  cell lines. To 
represent a broad range of NET subtypes, well-established cell 
line NET models from pancreas (BON, QGP-1), colon (LCC-18), 
and lung (H727, UMC-11) were included.
Treatment with a 137Cs source yielded a measure for the in vitro 
sensitivity of the cells toward ionizing radiation: the dose required 
to diminish cell number by 50% of control was found to be in a 
close range, between 4 and 6 Gy. However, octreotide applied as a 
pretreatment did not alter cell number or cell cycle distribution in 
any of the cell lines (Figure 1), indicating a lack of radiosensitiza-
tion by the drug. External gamma radiation delivery has been 
chosen here, because it delivers reproducible, stable, and precise 
dose levels to cells in culture. Yet, the results obtained may not be 
fully predictive of PRRT using beta emitters as the latter exhibits 
differences in the nature of radiation, its energy spectrum, and 
kinetics. Radiopharmaceutical treatment will also depend on 
more complex phenomena such as biodistribution and tissue 
clearance kinetics, all potentially leading to differences in DNA 
profiles as well as damage recognition and repair mechanisms.
To verify whether SSA treatment alone would have an impact 
on viability or proliferation, cells were submitted to octreotide 
treatment up to a concentration of 20 µM. However, the drug did 
neither influence metabolic activity nor cell number (Figure 2). 
Direct and indirect antitumor effects of somatostatin and SSAs 
via SSTRs have so far been studied mostly in overexpression 
systems involving non-neuroendocrine, in part non-human cell 
lines such as CHO, COS, and HEK293 (8). Studies demonstrating 
a clear antiproliferative effect of SSAs in human neuroendocrine 
cell lines in vitro are scarce—mostly the impact was observed at 
concentrations of 1–10  μM, several orders of magnitude above 
published EC50 values for SSAs on SSTRs (0.2–10 nM) (7, 26, 27). 
One potential cause for the octreotide resistance of the five cell 
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lines under investigation in this study may be a lack of target 
expression. Indeed, radioligand binding experiments and gene 
expression analysis demonstrated low binding and expression of 
SSTRs (Figure 3). BON and UMC-11 cells showed some binding; 
however, this could not be displaced by octreotide (Figure 3A). 
Direct comparison of SSTR mRNA levels in these cell lines with 
levels in normal human tissue and human NET tissues showed 
considerably lower expression of most SSTRs in the cell lines than 
in the tumors. For the most important target of octreotide, SSTR2, 
mRNA levels were at least one, typically three orders of magnitude 
lower in the cell lines than in human tumors. These results strongly 
suggested that a lack of target expression, particularly of SSTR2, 
might have caused the octreotide resistance observed in these cell 
lines. SSTR mRNA expression in NET cell lines has been studied 
before (28–30). To the best of our knowledge, this is the first study 
to directly compare expression levels in NET cell lines as well as 
human normal and NET tissues in a quantitative manner.
In order to verify the hypothesis that re-expression of SSTR2 
may rescue octreotide sensitivity, two of the cell lines were 
transfected with a plasmid encoding human SSTR2. Successful re-
expression in BON and QGP-1 cells at levels similar to those found 
in human NET tissues led to functional cell surface expression, 
as confirmed by octreotide-induced radioligand displacement, 
immunofluorescence, and ligand-induced receptor internaliza-
tion (Figure 4). However, viability of these transfected cells under 
octreotide treatment up to 10 µM was still unaffected, indicating 
there must be further causes for this SSA resistance (Figure 5). 
A partial response with single-digit nanomolar IC50 was observed 
in RIN-1038 rat insulinoma cells transfected with rat SSTR2-GFP 
yet not in the parental wild-type cells, demonstrating the principle 
feasibility of this approach in a neuroendocrine cell line. This, in 
conjunction with the subnanomolar to low nanomolar IC50 values 
obtained in the radioligand binding assays (Figure 4B) and with 
the octreotide activity seen in the internalization assay (Figure S2 
in Supplementary Material), provides solid evidence for the integ-
rity and potency of the octreotide used here. However, two human 
NET cell lines could not be resensitized to SSA treatment by re-
establishing their SSTR2 expression. Obviously, other mechanisms 
such as a lack in one or more signal transduction components that 
would relay a signal from the receptor to the cell cycle machinery 
are in place in BON and QGP-1 cells, preventing them from 
responding to octreotide. The signal was shown to be relayed at 
least on to the β-arrestin/dynamin-associated vesicle formation 
and internalization machinery in both SSTR2-transfected cell 
lines, as otherwise the translocation of the receptor to an intracel-
lular vesicle compartment (Figure S2 in Supplementary Material; 
Figure 4D) would not occur. Antiproliferative and proapoptotic 
action of SSAs has been proposed to be transduced, e.g., via tyros-
ine phosphatases and ERK/Akt signaling (8). It is intriguing to 
speculate that signaling components essential for these pathways 
may have been lost in these cells or may never have been part of 
these cells’ inventory. There is no evidence yet from clinical studies 
that antiproliferative SSA action directly targets tumor cells rather 
than endothelial, immune or other cells of the tumor microen-
vironment. At least two large clinical trials have demonstrated 
antiproliferative effects of SSAs in NET patients (4, 5). As evidence 
for a direct action of SSAs on tumor cells in vivo is not available, a 
different mode of action should be considered, specifically on cells 
in the tumor microenvironment. The contribution of drug effects 
on cancer-associated fibroblasts, endothelial cells, macrophages, 
and other immune cells has been discussed as an antitumor 
mechanism in NETs and other tumor entities (31–35).
The lack of relevant SSTR expression levels in all five cell 
lines as well as ras and p53 mutations identified in some of them 
untypical for NET (36) call into question the suitability of these 
and other established NET cell lines as models to study regulation 
by SSAs (and potentially other drugs). In this set of experiments, 
different passages, including the earliest available for the respec-
tive cell line, were studied. Yet, no differences were identified 
in SSTR expression levels (see low variance in Figure 3B). Still, 
receptor downregulation and other perturbations may have 
occurred early on during the establishment of these cells lines and 
their adaptation from an in vivo tumor to 2D culture on plastic 
with artificial media and fetal calf serum, in the absence of an 
authentic microenvironment. During the past 40 years, work with 
continuously growing cell lines has greatly contributed to basic as 
well as translational cancer research. However, attention should 
be given in choosing the optimal in vitro model for the respective 
scientific question and analytical approach. Continuous NET cell 
lines frequently seem to lack SSTRs: for two novel large cell 
NET  cell lines, SSTRs could not be detected by immunohisto-
chemistry (37). On the other hand, two out of three proposed 
midgut NET  cell lines reported by Pfragner et  al. responded 
well to octreotide treatment (38, 39). Similarly, midgut NET cell 
lines KRJ and GOT1 seem to express SSTRs at functional levels 
(40, 41). However, three of the aforementioned cell lines (KRJ, 
H-STS, and L-STS) were recently characterized as non-neuroen-
docrine, EBV-positive lymphoblastoid cells (42). NET cell lines 
of pancreatic origin with authentic SSTR expression were lacking 
until Benten et al. recently published the establishment of the first 
well-differentiated human pancreatic NET cell line (43). Primary 
cell cultures from NET tissue may represent more authentic, 
relevant models and have proven valuable in the investigation 
of NET physiology in the past (44–47). Likewise, organoid and 
other 3D cultures may develop as an option to improve relevance 
and translatability of in vitro research. Furthermore, more bona 
fide in vivo models such as patient-derived xenografts may assist 
in verifying results from traditional NET cell lines (48).
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